Clorox (CLX) Receives a Hold from Wells Fargo
In a report released on February 15, Christopher Carey from Wells Fargo maintained a Hold rating on Clorox, with a price target of $125.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Carey is a 3-star analyst with an average return of 2.1% and a 50.34% success rate. Carey covers the Consumer Defensive sector, focusing on stocks such as Church & Dwight, Conagra Brands, and Anheuser-Busch Inbev Sa.
In addition to Wells Fargo, Clorox also received a Hold from Rothschild & Co Redburn’s Edward Lewis in a report issued on February 13. However, on February 4, Barclays maintained a Sell rating on Clorox (NYSE: CLX).
Based on Clorox’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.67 billion and a net profit of $157 million. In comparison, last year the company earned a revenue of $1.69 billion and had a net profit of $193 million
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CLX in relation to earlier this year. Most recently, in November 2025, Pierre Breber, a Director at CLX bought 4,000.00 shares for a total of $416,480.00.
Read More on CLX:
